# Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

> **NCT00322517** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 90 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** SU014813

## Key facts

- **NCT ID:** NCT00322517
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-06
- **Final completion:** 2009-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322517, "Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00322517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*